Jyothy Labs (532926) Q4 20/21 earnings summary

Executive summary

• FY21 consolidated revenue rose 11.6% to ₹1,909 crore; PAT increased 17.3% to ₹190.7 crore, with EBITDA up 25.3% to ₹314.5 crore.

• Resilient demand, rural reach, in-house manufacturing and pandemic-focused hygiene launches supported performance through lockdown disruption.

Financial highlights

• Consolidated revenue from operations was ₹1,909.1 crore versus ₹1,711.2 crore in FY20; gross margin was 47.1% versus 47.4%.

• Operating EBITDA was ₹314.5 crore, up 25.3%, with margin at 16.5% versus 14.7%; PAT was ₹190.7 crore versus ₹162.6 crore.

• PBT before exceptional item reached ₹258.1 crore versus ₹185.3 crore, up 39.3%; reported consolidated PAT was ₹190.65 crore.

• Standalone revenue increased 13.19% to ₹1,885 crore and PAT grew 20.65% to ₹190.3 crore.

Outlook and guidance

• Outlook was described as very positive; focus areas include deeper rural distribution, brand investment, digital adoption, innovation and sustainability.

• E-commerce partnerships and omnichannel availability are priorities as online household shopping habits are expected to persist alongside general trade.

• Continuous Replenishment System reduced distributor pipeline stock from 22–25 days in FY20 to 8–10 days in FY21.